AIP
CRL icon

Ahrens Investment Partners’s Charles River Laboratories CRL Stock Holding History

Ahrens Investment Partners’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		$4.24K Buy
+21
New +$4.76K ﹤0.01% 790
2022
Q3 		– Sell
-21
Closed -$4K – 310
2022
Q2 		$4K Hold
21
– – ﹤0.01% 791
2022
Q1 		$6K Hold
21
– – ﹤0.01% 817
2021
Q4 		$8K Buy
+21
New +$8.16K ﹤0.01% 784

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Ahrens Investment Partners's CRL Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Charles River Laboratories (CRL) in Q1 2023: 21 shares worth $4.24K. The stake represents ﹤0.01% of the portfolio and ranks #790 among its holdings. This is a return to the name: Ahrens Investment Partners previously reported a position in CRL as recently as Q2 2022.

Ahrens Investment Partners first reported a position in CRL in Q4 2021 and has held it in 4 quarters since. The position peaked at $8K in Q4 2021. 620 funds tracked by Wall St. Rank hold CRL as of Q1 2023.

  • Ahrens Investment Partners held 21 shares of Charles River Laboratories worth $4.24K as of Q1 2023.
  • Charles River Laboratories was a new Ahrens Investment Partners position in Q1 2023.
  • Charles River Laboratories made up ﹤0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #790 holding.
  • Ahrens Investment Partners first reported a position in Charles River Laboratories in Q4 2021 and has held it in 4 quarters since.
  • Ahrens Investment Partners's Charles River Laboratories position peaked at $8K in Q4 2021.
  • 620 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.